Application of multi-state models in cancer clinical trials.
Ontology highlight
ABSTRACT: Background/aims The goal of this article is to illustrate the utility of multi-state models in cancer clinical trials. Our specific aims are to describe multi-state models and how they differ from standard survival methods, to illustrate how multi-state models can facilitate deeper understanding of the treatment effect on multiple paths along the disease process that patients could experience in cancer clinical trials, to explain the differences between multi-state models and time-dependent Cox models, and to briefly describe available software to conduct such analyses. Methods Data from 717 newly diagnosed acute myeloid leukemia patients who enrolled in the CALGB 10603 trial were used as an illustrative example. The current probability-in-state was estimated using the Aalen-Johansen estim
SUBMITTER: Le-Rademacher JG
PROVIDER: S-EPMC6133743 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA